Institution
Kenya Medical Research Institute
Facility•Nairobi, Kenya•
About: Kenya Medical Research Institute is a facility organization based out in Nairobi, Kenya. It is known for research contribution in the topics: Population & Malaria. The organization has 3488 authors who have published 6023 publications receiving 271690 citations. The organization is also known as: KEMRI.
Topics: Population, Malaria, Plasmodium falciparum, Anopheles gambiae, Acquired immunodeficiency syndrome (AIDS)
Papers published on a yearly basis
Papers
More filters
Theo Vos1, Amanuel Alemu Abajobir, Kalkidan Hassen Abate2, Cristiana Abbafati3 +775 more•Institutions (305)
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) provides a comprehensive assessment of prevalence, incidence, and years lived with disability (YLDs) for 328 causes in 195 countries and territories from 1990 to 2016.
10,401 citations
University of North Carolina at Chapel Hill1, Fred Hutchinson Cancer Research Center2, FHI 3603, University of Zimbabwe4, Johns Hopkins University5, Oswaldo Cruz Foundation6, Chiang Mai University7, Fenway Health8, Harvard University9, Kenya Medical Research Institute10, University of the Witwatersrand11, University of California, San Francisco12, University of Nebraska Medical Center13, National Institutes of Health14, University of California, Los Angeles15, University of Washington16
TL;DR: In this article, Antiretroviral therapy that reduces viral replication could limit the transmission of human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples.
Abstract: Background Antiretroviral therapy that reduces viral replication could limit the transmission of human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples. Methods In nine countries, we...
5,871 citations
Gregory A. Roth1, Gregory A. Roth2, Degu Abate3, Kalkidan Hassen Abate4 +1025 more•Institutions (333)
TL;DR: Non-communicable diseases comprised the greatest fraction of deaths, contributing to 73·4% (95% uncertainty interval [UI] 72·5–74·1) of total deaths in 2017, while communicable, maternal, neonatal, and nutritional causes accounted for 18·6% (17·9–19·6), and injuries 8·0% (7·7–8·2).
5,211 citations
Jeffrey D. Stanaway1, Ashkan Afshin1, Emmanuela Gakidou1, Stephen S Lim1 +1050 more•Institutions (346)
TL;DR: This study estimated levels and trends in exposure, attributable deaths, and attributable disability-adjusted life-years (DALYs) by age group, sex, year, and location for 84 behavioural, environmental and occupational, and metabolic risks or groups of risks from 1990 to 2017 and explored the relationship between development and risk exposure.
2,910 citations
University of Washington1, Fred Hutchinson Cancer Research Center2, University of Nairobi3, Centers for Disease Control and Prevention4, The AIDS Support Organization5, University of California, San Francisco6, Makerere University7, University of Manitoba8, Moi University9, Indiana University – Purdue University Indianapolis10, Kenya Medical Research Institute11, Boston Children's Hospital12, Johns Hopkins University13, Harvard University14, University of the Witwatersrand15
TL;DR: Oral TDF and TDF-FTC both protect against HIV-1 infection in heterosexual men and women, and both study medications significantly reduced the HIV- 1 incidence among both men andWomen.
Abstract: Background Antiretroviral preexposure prophylaxis is a promising approach for preventing human immunodeficiency virus type 1 (HIV-1) infection in heterosexual populations. Methods We conducted a randomized trial of oral antiretroviral therapy for use as preexposure prophylaxis among HIV-1–serodiscordant heterosexual couples from Kenya and Uganda. The HIV-1–seronegative partner in each couple was randomly assigned to one of three study regimens — once-daily tenofovir (TDF), combination tenofovir–emtricitabine (TDF–FTC), or matching placebo — and followed monthly for up to 36 months. At enrollment, the HIV-1–seropositive partners were not eligible for antiretroviral therapy, according to national guidelines. All couples received standard HIV-1 treatment and prevention services. Results We enrolled 4758 couples, of whom 4747 were followed: 1584 randomly assigned to TDF, 1579 to TDF–FTC, and 1584 to placebo. For 62% of the couples followed, the HIV-1–seronegative partner was male. Among HIV-1–seropositive par...
2,752 citations
Authors
Showing all 3540 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Simon I. Hay | 165 | 557 | 153307 |
| Silvia Franceschi | 155 | 1340 | 112504 |
| Thomas N. Williams | 132 | 1145 | 95109 |
| Kevin Marsh | 128 | 567 | 55356 |
| Robert W. Snow | 117 | 489 | 48427 |
| Ronald N. Germain | 110 | 294 | 41107 |
| Robert F. Breiman | 105 | 473 | 43927 |
| Frank H. Collins | 96 | 342 | 44638 |
| David L. Smith | 96 | 331 | 47666 |
| Charles R. Newton | 91 | 504 | 73772 |
| Andrew J. Tatem | 90 | 356 | 27990 |
| David A. Warrell | 89 | 484 | 27043 |
| Francis A. Plummer | 85 | 317 | 24228 |
| Peter Piot | 82 | 559 | 28489 |
| Simon Brooker | 81 | 274 | 37565 |